Mark Kawakami's most recent trade in Arcadia Biosciences Inc was a trade of 700 Common Stock done at an average price of $2.5 . Disclosure was reported to the exchange on Feb. 3, 2025.
Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
---|---|---|---|---|---|---|---|---|---|---|
Arcadia Biosciences Inc | Mark Kawakami | Chief Financial Officer | Purchase of securities on an exchange or from another person at price $ 2.49 per share. | 03 Feb 2025 | 700 | 2,681 (0%) | 0% | 2.5 | 1,743 | Common Stock |
Arcadia Biosciences Inc | Mark Kawakami | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Aug 2024 | 20,000 | 21,487 | - | - | Stock Option (Right to Buy) | |
Arcadia Biosciences Inc | Mark Kawakami | Chief Financial Officer | Purchase of securities on an exchange or from another person at price $ 2.06 per share. | 01 Aug 2024 | 700 | 1,981 (0%) | 0% | 2.1 | 1,442 | Common Stock |